Living Cell Technologies Limited Company Profile

Living Cell Technologies (LCT) is an Australasian biotechnology company
improving the wellbeing of people with serious diseases worldwide by
discovering, developing and commercializing regenerative treatments that
restore function using naturally occurring cells. LCTâs unique
proprietary encapsulation delivery technology, IMMUPELâ¢, coats cells
with protective capsules that prevent them from attack by the immune
system. This allows cell therapies to be used without the need for
immunosuppressive drugs. LCTâs lead product, NTCELLÂ®, is
being developed for neurodegenerative diseases. LCT recently completed a
Phase I/IIa clinical trial of NTCELL in New Zealand for the treatment of
Parkinsonâs disease and plans to initiate a Phase IIb study in the
fourth quarter of 2015. LCT holds a 50 percent interest in Diatranz
Otsuka Limited, which is developing DIABECELLÂ®, a cell
therapy in late-stage clinical trials for the treatment of type 1
diabetes. LCT is listed on the Australian (ASX: LCT) and United States
(OTCQX: LVCLY) stock exchanges. The company is incorporated in
Australia, with research and development and operations based in New
Zealand. For more information, visit www.lctglobal.com
or follow @lctglobal
on Twitter.

The term live cell imaging collectively refers to the technologies used to capture images of cells in a living, active state, either as individual static pictures or as time-lapse series. Correspondin...

Cell and Molecular Therapies (CMT), Royal Prince Alfred Hospital are committed to the development of novel cell therapies and the subsequent improvement in survival and quality of life of patients who...

(Georgia Institute of Technology) Researchers have demonstrated an integrated technique for monitoring specific biomolecules -- such as growth factors -- that could indicate the health of living cell ...

Bidirectional promoters (BPs) are prevalent in eukaryotic genomes. However, it is poorly understood how the cell integrates different epigenomic information, such as transcription factor (TF) binding ...

There is a growing interest in the design and engineering of operational biofuel cells that can be implanted. This review highlights the recent progress in the electrochemistry of biofuel cell technol...

Chip-man Technolgies was formed in 2002 from researchers from the University of Tampere, Technical University of Tampere and the Finnish Research Organisation, VTT. The founders combined expertise to ...

Atto Bioscience is changing the way cell analysis is done. With systems that allow real-time kinetic imaging of individual cells within a population, Atto Bioscience provides integrated solutions for ...